We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 2 of 13 for:    Avatrombopag | ITP

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04638829
Recruitment Status : Recruiting
First Posted : November 20, 2020
Last Update Posted : November 3, 2022
Information provided by (Responsible Party):
Sobi, Inc.

Brief Summary:
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia Drug: Avatrombopag Oral Tablet Phase 4

Detailed Description:
This Phase 4, prospective, multi-center, open-label study will evaluate safety, platelet count, and subject reported medication satisfaction in adult subjects with chronic ITP after switching to avatrombopag from eltrombopag or romiplostim. At least 100 subjects will be enrolled, 50 (±10) who have received eltrombopag and 50 (±10) who have received romiplostim for at least 90 days prior to study entry.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim
Actual Study Start Date : March 15, 2021
Estimated Primary Completion Date : March 31, 2023
Estimated Study Completion Date : May 23, 2023

Arm Intervention/treatment
Avatrombopag 20 mg oral tablet formulation for 90 days
Drug: Avatrombopag Oral Tablet
Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
Other Name: Doptelet

Primary Outcome Measures :
  1. Safety and Tolerability (adverse events) [ Time Frame: Screening through Day 90 or End of Study ]

    Safety and Tolerability of Avatrombopag given for 90 days after stopping eltrombopag or romiplostim

    The incidence and severity of adverse events (AEs), serious adverse events (SAE) and adverse events of special interest (AESIs) will be summarized for all enrolled subjects using counts and percentages. Treatment-emergent AEs and SAEs will be summarized overall, by system organ class, and by preferred term. AESIs will be summarized by event type (thromboembolic events and bleeding events). In addition, treatment-emergent AEs will be summarized by severity and by relationship to study drug.

    Bleeding events reported during the study will be summarized by WHO grade.

Secondary Outcome Measures :
  1. Subject reported outcomes [ Time Frame: Screening through Day 90 or End of Study ]
    Evaluate the change in subject reported outcomes (TSQM questionnaire) from Baseline after switching to avatrombopag from eltrombopag or romiplostim

  2. Platelet counts [ Time Frame: Screening through Day 90 or End of Study ]
    Evaluate the platelet counts after switching to avatrombopag from eltrombopag or romiplostim

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has been undergoing treatment for primary ITP with eltrombopag or romiplostim for at least 90 days prior to the Screening Visit/Visit 1.
  • Subject has had a previous response (at any time) to either eltrombopag or romiplostim, defined as at least 2 platelet counts ≥50×10⁹/L. Subject is willing and able to comply with all aspects of the protocol, including completing the self-administered Treatment Satisfaction Medication Questionnaire (TSQM).

Exclusion Criteria:

  • Subject is currently receiving chemotherapy or radiation for any form of cancer.
  • Subject with conditions that are likely to prevent them from accurately and reliably completing study assessments, including evidence of moderate to severe dementia, and/or severe and progressive medical illness, as determined by the Investigator.
  • Any previous avatrombopag use.
  • Previous participation in this study; a subject may not re-enroll after prior discontinuation or completion.
  • Enrollment in another clinical study with any investigational drug or device within 30 days of Baseline (or 5 half-lives, whichever is longer); however, participation in observational studies within the previous 30 days is permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04638829

Layout table for location contacts
Contact: Sobi Clinical 984-255-4872 NAClincal@Sobi.com

Show Show 17 study locations
Sponsors and Collaborators
Sobi, Inc.
Layout table for additonal information
Responsible Party: Sobi, Inc.
ClinicalTrials.gov Identifier: NCT04638829    
Other Study ID Numbers: AVA-ITP-401
First Posted: November 20, 2020    Key Record Dates
Last Update Posted: November 3, 2022
Last Verified: October 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sobi, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Skin Manifestations